Skip to content
TickerMagic

EMCURE PHARMACEUTICALS L

EMCURENSEHealthcare
₹2,344.7
+9.90 (+0.42%) · EOD 2026-11-20

Our verdict

Buy

Momentum (93/100) does the heavy lifting; valuation (31/100) is the drag.

Fair valueHealth A
Quality 64Momentum 93Value 31Trend 76The Spark ↓

Our fair value

Overvalued by 21%
₹1,856.8down 20.81%
Price ₹2,345Range ₹1,172 – ₹2,311

Buy-below (20% margin of safety): ₹1,485.44

The bottom line

EMCURE PHARMACEUTICALS L earns a Buy from TickerMagic, with a blended score of 62/100. On 37.8x trailing earnings it sits roughly in line with the Healthcare median of about 37.4x. It's trading right at its 52-week high of ₹2,361.7. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹1,913.5 implies about 18% downside across 6 analysts. It clears 9 of 13 investability checks, with durability 64, valuation 46 and momentum 93 on our 0–100 scales.

Analysis by Ankit Sharma · TickerMagic's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.

Intrinsic value
Our fair value
₹1,856.8down 20.81%
Overvalued by 21%
Price ₹2,344.7Range ₹1,172.35–₹2,310.55
DCF + relative blendhigh confidence

With a 20% margin of safety, our buy-below price is ₹1,485.44.

Analyst views

6 analysts5 buy · 1 hold · 0 sell
12-month consensus target₹1,913.5down 18.39%

1-year price

EOD · 2026-11-20
1D
up 0.42%
1W
up 1.31%
1M
up 32.72%
3M
up 25.33%
6M
up 37.37%
1Y
—

52-week range

-0.72% from the 52-week high.

Trend check
Above 50-DMA₹1,984Above 200-DMA₹1,766

Price above both moving averages reads as an intact uptrend; below both, the trend is against you.

Verdict pillars

Buy62
A
Financial health 100/100
Altman Z 6.17 · Safe zone

Piotroski F-score 4/9 — quality of earnings & balance sheet.

Our scores

Durability64
Valuation46
Momentum93

Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.

Investability checklist

Passed 9 of 13 checks
Each check screens one fundamentals, valuation or trend signal.
  • Pass: ROE above 15%: 19.6%
  • Pass: Low debt (D/E < 0.5): 0.31x
  • Pass: Positive free cash flow
  • Pass: Revenue growth > 10%: 17%
  • Pass: Earnings growing: 29%
  • Pass: Net margin ≥ 10%: 10.0%
  • Fail: Current ratio > 1.5: 1.43
  • Fail: Below our fair value
  • Fail: Margin of safety ≥ 20%
  • Pass: Above 200-day average
  • Pass: Above 50-day average
  • No data: Positive 1-year return
  • Pass: Altman Z in safe zone: Z 6.17
  • Fail: Piotroski ≥ 7: 4/9

Quarterly results

Revenue · 1Q2026
₹2,470 Cr
Net profit
₹279 Cr
Margin
11%
2Q2025
3Q2025
4Q2025
1Q2026
Revenue Net profitLatest revenue QoQ +4%

Annual financials

Revenue · 2026
₹9,204 Cr
Net profit
₹991 Cr
Margin
11%
2025
2026
Revenue Net profitLatest revenue YoY +17%

Shareholding

  • Promoter81.7%
  • Institutions5.4%
  • Public & other12.9%

Promoter holding via insider stake; institutional via reported holdings.

Key fundamentals

Market cap
₹34,903 Cr
P/E ratio
37.8
P/B ratio
7.05
EPS (TTM)
₹48.68
ROE
19.6%
Debt / Equity
0.31x
Profit margin
10.0%
Free cash flow
₹311 Cr
52-week high
₹2,361.7
-0.72% from high
52-week low
₹1,351.97
Dividend yield
0.2%
Beta
—
SWOT snapshot

Bull case vs bear case

Bull case

Strengths

  • Strong return on equity (19.6%).
  • Lightly leveraged balance sheet.
  • Trading near its 52-week high.
  • Financially solid — Altman Z 6.17.

Opportunities

  • Earnings growing (29% YoY).
  • Revenue growing (17% YoY).

Bear case

Threats

  • Trades ~21% above our estimated fair value.

About EMCURE PHARMACEUTICALS L

Emcure Pharmaceuticals Limited manufactures and distributes pharmaceutical products across multiple therapeutic areas including gynecology, anti-infectives, pain management, vitamins and minerals, oncology, respiratory, HIV antivirals, gastroenterology, anti-diabetes, neurology, and cardiovascular treatments. The company markets its products under brand names including Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym.

EMCURE PHARMACEUTICALS L — frequently asked questions

Is EMCURE PHARMACEUTICALS L a buy, hold or sell?

TickerMagic currently rates EMCURE PHARMACEUTICALS L (EMCURE) a Buy, based on a blended score of 62/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.

What is EMCURE PHARMACEUTICALS L's fair value?

Our blended DCF and relative-valuation model estimates EMCURE PHARMACEUTICALS L's fair value at about ₹1,856.8, versus a current price of ₹2,344.7 — roughly 21% downside. On that basis the stock looks overvalued by 21%.

Is EMCURE PHARMACEUTICALS L financially healthy?

EMCURE PHARMACEUTICALS L scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.

How has EMCURE PHARMACEUTICALS L's share price performed?

EMCURE PHARMACEUTICALS L is up 25% over three months, and last traded at ₹2,344.7. Past performance doesn't predict future returns.

Our verdict, fair value, financial-health and checklist are TickerMagic's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.